Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.37 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.37 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12981139 | 0.88 | ESR1 (0.42) | CYP1A2CYP2D6CYP2C19LMNANPC1 | |
| SCHEMBL25826743 | 0.85 | CYP1A2 (0.43) | CYP1A2CYP2D6CYP2C19LMNANPC1 | |
| SCHEMBL25827992 | 0.81 | CYP1A2 (0.41) | CYP1A2CYP2D6CYP2C19LMNANPC1 | |
| SCHEMBL30338274 | 0.81 | TAAR1 (0.43) | LMNAMAPK1ESR1ESR2TAAR1 | |
| SCHEMBL25825947 | 0.80 | LMNA (0.46) | CYP1A2CYP2D6CYP2C19LMNANPC1 | |
| SCHEMBL7376865 | 0.80 | SLC6A2 (0.48) | CYP2D6LMNAMAPK1SMN1; SMN2TAAR1 | |
| SCHEMBL24425444 | 0.79 | TAAR1 (0.39) | CYP1A2CYP2D6CYP2C19LMNAMAPK1 | |
| SCHEMBL11730046 | 0.79 | MAPT (0.44) | CYP1A2CYP2D6CYP2C19NPC1MAPK1 | |
| SCHEMBL27616405 | 0.78 | TAAR1 (0.39) | LMNAMAPK1ESR1TAAR1HTR2A | |
| SCHEMBL21654179 | 0.78 | ESR1 (0.41) | LMNASMN1; SMN2ESR1ESR2TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219942-A1 | COMPOUNDS COMPRISING A THREE RING CORE AS PD-1/PD-L1 BLOCKERS | RELIVE THERAPEUTICS INC. (CA) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219942-A1 | COMPOUNDS COMPRISING A THREE RING CORE AS PD-1/PD-L1 BLOCKERS | CD274, PDCD1, PDCD1LG2 | CYP1A2 1307/4885CYP2D6 1571/4885CYP2C19 2291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.